Meds & supplements › Benzhydrocodone
Medicine
APADAZ is indicated for the short-term (no more than 14 days) management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.
Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗
Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, which can occur at any dosage or duration reserve APADAZ for use in patients for whom alternative treatment options [e.g., non-opioid analgesics]:
APADAZ should not be used for an extended period of time unless the pain remains severe enough to require an opioid analgesic and for which alternative treatment options continue to be inadequate.
The following serious adverse reactions are described, or described in greater detail, in other sections:
APADAZ is contraindicated in patients with:
sofidex [Internet]. Daloreum; c2026. Benzhydrocodone; [reviewed 2026 Aug 2; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/benzhydrocodone
sofidex. (2026, August 2). Benzhydrocodone. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/benzhydrocodone
Benzhydrocodone. sofidex. Reviewed August 2, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/benzhydrocodone
The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.